Grifols, S.A. Share Price

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate 07:04:29 17/07/2024 pm IST 5-day change 1st Jan Change
9.199 EUR +0.60% Intraday chart for Grifols, S.A. -8.99% -40.41%

Financials

Sales 2024 * 7.1B 7.76B 649B Sales 2025 * 7.61B 8.32B 695B Capitalization 5.75B 6.29B 526B
Net income 2024 * 431M 472M 39.4B Net income 2025 * 655M 717M 59.87B EV / Sales 2024 * 2.1 x
Net Debt 2024 * 9.16B 10.02B 837B Net Debt 2025 * 8.62B 9.43B 788B EV / Sales 2025 * 1.89 x
P/E ratio 2024 *
13.8 x
P/E ratio 2025 *
9.18 x
Employees 23,000
Yield 2024 *
0.5%
Yield 2025 *
1.72%
Free-Float 75.84%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.49%
1 week-8.99%
Current month+17.18%
1 month+0.70%
3 months+4.26%
6 months+6.84%
Current year-40.41%
More quotes
1 week
8.95
Extreme 8.952
10.13
1 month
7.77
Extreme 7.77
10.81
Current year
6.36
Extreme 6.362
15.63
1 year
6.36
Extreme 6.362
15.92
3 years
6.36
Extreme 6.362
22.64
5 years
6.36
Extreme 6.362
34.31
10 years
6.36
Extreme 6.362
34.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 06/02
Director of Finance/CFO 67 01/07/01
Chairman 65 05/06/05
Members of the board TitleAgeSince
Chairman 65 05/06/05
Director/Board Member 68 13/00/13
Director/Board Member 59 29/15/29
More insiders
Date Price Change Volume
17/24/17 9.212 +0.74% 555 076
16/24/16 9.144 -0.72% 2,338,880
15/24/15 9.21 -6.35% 3,317,493
12/24/12 9.834 -1.91% 2,250,162
11/24/11 10.02 -0.94% 3,078,319

Delayed Quote BME, July 17, 2024 at 06:49 pm IST

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
9.144 EUR
Average target price
17.22 EUR
Spread / Average Target
+88.34%
Consensus